We are uncertain as to how Klungel and colleagues derived the information that 13.5% of our study subjects in the high-normal or hypertensive categories were eligible for initial drug therapy. As stated in our article,1 we calculated that 60.6% of these subjects were eligible for initial drug therapy or were already receiving drug therapy. If we consider only untreated subjects, 476 (32.0%) of 1488 fell into one of the following categories for which the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI) recommends initial drug therapy: (1) stage 2 or stage 3 hypertension, (2) stage 1 hypertension in risk group C, or (3) high-normal blood pressure with congestive heart failure or diabetes. These 476 subjects represent 17.0% of all 2794 subjects (treated and untreated with high-normal blood pressure or hypertension).
Lloyd-Jones DM, Levy D. Overestimation of the Number of Individuals With Hypertension Who Are Eligible for Treatment According to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure—Reply. Arch Intern Med. 2000;160(10):1537–1538. doi:
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: